Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institute of Health, Bethesda, Maryland.
Am J Trop Med Hyg. 2018 Oct;99(4):827-832. doi: 10.4269/ajtmh.17-0895.
In August 2017, the National Institute of Allergy and Infectious Diseases convened a meeting, entitled "Understanding the Liver-Stage Biology of Malaria Parasites to Enable and Accelerate the Development of a Highly Efficacious Vaccine," to discuss the needs and strategies to develop a highly efficacious, whole organism-based vaccine targeting the liver stage of malaria parasites. It was concluded that attenuated sporozoite platforms have proven to be promising approaches, and that late-arresting sporozoites could potentially offer greater vaccine performance than early-arresting sporozoites against malaria. New knowledge and emerging technologies have made the development of late-arresting sporozoites feasible. Highly integrated approaches involving liver-stage research, "omics" studies, and cutting-edge genetic editing technologies, combined with in vitro culture systems or unique animal models, are needed to accelerate the discovery of candidates for a late-arresting, genetically attenuated parasite vaccine.
2017 年 8 月，国家过敏和传染病研究所召开了一次题为“了解疟原虫的肝脏阶段生物学，以开发高效疫苗”的会议，讨论了开发针对疟原虫肝脏阶段的高效、全生物体疫苗的需求和策略。会议得出结论，减毒子孢子平台已被证明是很有前途的方法，晚期停滞子孢子可能比早期停滞子孢子提供更大的疟疾疫苗性能。新的知识和新兴技术使得开发晚期停滞子孢子成为可能。需要采用高度综合的方法，包括肝脏阶段研究、“组学”研究和尖端的基因编辑技术，结合体外培养系统或独特的动物模型，以加速发现具有晚期停滞、遗传减毒寄生虫疫苗的候选物。
